Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers.
Reviewed by Danielle Ellis, B.Sc.Aug 25 2023 Advice to lower that risk is launched today in the 2023 European Society of Cardiology Guidelines for the management of cardiovascular disease in patients with diabetes, published in European Heart Journal.
The Guidelines recommend lifestyle changes for all patients with diabetes to reduce the likelihood of CVD. In obese patients with diabetes, weight reduction is one of the cornerstones of treatment, and the Guidelines recommend weight reduction and daily exercise. All patients with diabetes should stop smoking and adopt a Mediterranean or plant-based diet high in unsaturated fat to lower cardiovascular risk.
Related StoriesA special focus of the Guidelines is managing heart failure in patients with diabetes. Those with diabetes have a two- to four-fold risk of developing heart failure compared to patients without diabetes and many are unaware that they have heart failure. The Guidelines recommend systematic screening for heart failure signs and symptoms during each clinical encounter to allow early use of life-saving therapies.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
New ESC Guidelines on cardiomyopathies published online todayThe European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online today in European Heart Journal.
Lire la suite »
Newly published ESC Guidelines provide comprehensive overview of acute coronary syndromesThe European Society of Cardiology (ESC) Guidelines on acute coronary syndromes are published online today in European Heart Journal.
Lire la suite »
Drivers to face tougher sentences for killing pedestrians under new guidelinesThe Scottish Sentencing Council has produced its first guideline covering the offence of causing death by driving, with aggressive driving such as…
Lire la suite »
A new targeted treatment shows promise for select patients with stomach cancerAn international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, has found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.
Lire la suite »
New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancerAn international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.
Lire la suite »
Patients to face 'severe delays' as top doctors begin new strikeConsultants are walking out for the second time - and have said that they will do so again in September and October
Lire la suite »